Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 240 of 6351
-
Targeted pill may shrink lung tumors before surgery in new trial
Disease control OngoingA prospective, single-arm, open-label phase 2 study that evaluates the efficacy and safety of induction Lorlatinib in stage III non-small cell lung cancer and explores the clinical feasibility of dynamic ctDNA and multidisciplinary assessment in guiding local treatments.
Phase 2 • Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis is a prospective, open-label, dose-escalation and randomized dose optimization and expansion study. The Phase Ib portion of the study aims to determine the safety and tolerability of escalating doses of \[212Pb\]Pb-ADVC001 administered every 6, 4, 2 or 1 week(s) and establis…
Phase 1/2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Can a lotion calm the severe skin symptoms of netherton syndrome?
Disease control Recruiting nowTo assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome
Phase 2/3 • Sponsor: Quoin Pharmaceuticals • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo aims to stop breast cancer return in High-Risk patients
Disease control Recruiting nowNeratinib is an irreversible pan-HER tyrosine kinase inhibitor (TKI). Currently, no studies have investigated the use of macromolecular anti-HER2 agents combined with TKIs for the treatment of non-pCR HER2-positive breast cancer following neoadjuvant therapy. Furthermore, there a…
Phase 3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Could a simple shot replace IV drips for advanced melanoma?
Disease control OngoingThe purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unre…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could old drugs beat rare cancers? new trial aims to find out
Disease control Recruiting nowDETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Patients must have a cancer with an identified mutation. This could be found during routine testing or as part of another rese…
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a drug duo outsmart resistant tumors?
Disease control Recruiting nowAn open, non-randomized Phase Ib-II trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory neuroblastoma or solid tumors.
Phase 1/2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
A Finger-Prick could change the fight against hepatitis c
Diagnosis Recruiting nowThe goal of this observational study is to learn if offering a point-of-care screening test for exposure to the Hepatitis C virus, before providing a diagnostic test for Hepatitis C infection can increase testing, diagnosis and treatment in Adults. Participants will be recruited …
Sponsor: Kirby Institute • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
New pill could ease painful skin condition hidradenitis suppurativa
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Radioactive therapy vs chemotherapy: which works better for pancreatic NETs?
Disease control OngoingThis phase II trial compares the effect of combination therapy with capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body (advanced) or that cannot be removed by surgery (unresec…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo aims to fight untreatable liver cancer
Disease control OngoingThis is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New transplant approach could help more patients with blood disorders
Disease control Recruiting nowHematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs tha…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a daily vitamin slow the hardening of heart arteries?
Disease control Completed1\. Abstract Introduction Coronary artery calcification (CAC) and especially progression in CAC is a strong predictor of acute myocardial infarction and cardiovascular mortality. A substudy in the recent Danish study, AVADEC, suggested a protective role of supplementation with v…
Sponsor: Odense University Hospital • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a targeted drug tame advanced HER2-Positive breast cancer?
Disease control CompletedA single-center observational study (retrospective + prospective) evaluating the real-world efficacy and toxicity profile of Trastuzumab Deruxtecan (T-DXd) in adult female patients with HER2-positive metastatic breast cancer treated at KSAMC, Madinah, Saudi Arabia
Sponsor: Mansoura University • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a triple-drug cocktail re-sensitize lung cancer to treatment?
Disease control OngoingA Phase 2 Study of Pembrolizumab in Combination with Plinabulin and Docetaxel in previously treated Patients with Metastatic Non-Small Cell Lung Cancer and progressive disease (PD) after immunotherapy (Anti-PD-1/PD-L1 inhibitor) alone or in combination with Platinum-doublet Chemo…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Feeding kids tiny bits of allergens may help them beat food allergies
Disease control By invitation onlyThe goal of this clinical trial is to learn about oral immunotherapy in food allergic children \< 30 months of age. The main question it aims to answer is: What is the clinical- and cost-effectiveness of early low-dose oral immunotherapy aimed at long-term tolerance induction. Pa…
Sponsor: Deventer Ziekenhuis • Aim: Disease control
Last updated Jun 26, 2026 18:06 UTC
-
New triple therapy targets FLT3-Mutated leukemia in frail patients
Disease control OngoingPeople with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene. Gilteritinib, giv…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
A One-Two punch for long COVID? supplement and therapy put to the test
Disease control CompletedLong COVID, also referred to as post-acute sequela of COVID-19 (PASC), is present in a substantial number of individuals, and treatment for this is warranted. Two different hypothetical models of Long COVID suggest attenuated mitochondrial energy production and functional brain a…
Phase 2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for HIV patients with blood cancer: safer bone marrow transplants on the horizon?
Disease control Recruiting nowBackground: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a standard reason to need transplant. Objective: Thi…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New stroke prevention pill could cut risk without extra bleeding
Prevention CompletedResearchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: * an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke),…
Phase 3 • Sponsor: Bayer • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC